My opponent says lobbying is open to both sides, so it's argument, not purchase. But that's the practical problem: when outcomes track spending, the richest side wins by default. A patient group and a drug lobby aren't equally heard, and we all live with the result. My opponent is right that the 220 to 1 figure measures savings against spend, not favors bought. I'll grant that. But when a hundred million in lobbying reliably delivers a rule worth billions, the winner isn't the best argument. It's the biggest wallet. Functionally, that's bribery with paperwork.